The protean nature of the central nervous system tumors in NF2, incomplete understanding of their natural history, and undefined mechanism of symptom formation have resulted in a strategy of treating patients only after they develop neurologic deficits. By that time, tumors are typically large and neurological deficits irreversible. Surgical removal of large tumors often adds deficits. Better knowledge of NF2 natural history and tumor growth patterns could improve surgical timing and outcomes. We started a natural history study of NF2 patients 11 years ago to gain clinical and molecular insights into the effects of the type (missense, nonsense, deletion) of NF2 gene mutation on tumor development/progression and to identify features associated with symptom evolution in patients with NF2-associated tumors. The natural history study of NF2 initially enrolled 169 subjects, with the final subject completing follow-up evaluation in November 2018. This prospective natural history study identified factors that influenced tumor biology, symptom formation, and treatment outcome. Central nervous system tumors in NF2 usually contained many different populations of tumor cells. A saltatory growth pattern of periodic tumor growth was more often seen (59%) than linear (30%) or exponential growth (11%). Elevated intralabyrinthine protein and larger tumor size by MRI-scanning correlated with hearing loss. We published the first comprehensive whole exome sequencing study of NF2-related meningiomas. Sequencing of 2 adjacent intracranial meningiomas removed from the same patient showed that the second copy of the NF2 gene was inactivated in both tumors. The faster growing tumor, a Grade II meningioma, had a higher level of genomic instability than the slower-growing, Grade I meningioma. Long-term follow up of patients with NF2 was found to be essential in evaluating disease progression. However, because tumor growth and symptom production were unpredictable and new tumors developed in NF2 patients over their lifetime, we could not propose a better method for timing of tumor resection than the present practice of resecting only symptom-producing tumors. In February 2019, the study began enrollment of another 100 NF2 patients, who will undergo annual clinical and radiologic evaluations for 10 years as outpatients. Patients with NF2 have symptoms that significantly affect their lives, including hearing loss and speech/swallowing dysfunction. This previous stage of the NF2 natural history study helped us understand how these symptoms arise even from very small or quiescent tumors. In the ongoing study we seek to find better ways to prevent hearing loss and counsel patients about speech and swallowing problems. Auditory testing will be performed annually for participants with measurable hearing. Participants with initially untreated vestibular schwannomas will be followed annually with vestibular testing. Speech and swallowing reassessments will be performed if worsening of speech or swallowing is reported. Blood will be collected at each visit for blood biomarker testing. This recent cohort will allow us to further explore the biologic basis for speech and swallowing dysfunction in patients with NF2. We will study and report the strength of association of MRI findings, clinical assessments cranial nerve deficits and speech/swallowing dysfunction. We hope to identify imaging biomarkers of hearing loss in NF2. We will also explore other aspects of NF2, including attempting to discover the mode of peripheral neuropathy in patients with NF2 and to discover previously unknown serum biomarkers associated with high tumor burden in NF2.

Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
2019
Total Cost
Indirect Cost
City
State
Country
Zip Code
Donaldson, Katelyn; Scott, Gretchen; Cantor, Fredric K et al. (2018) Eccrine spiradenoma mimicking a painful traumatic neuroma: case report. J Neurosurg 129:825-828
Ho, Winson S; Sizdahkhani, Saman; Hao, Shuyu et al. (2018) LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation. Cancer Lett 415:217-226
deTorres, Alvin T; Brewer, Carmen C; Zalewski, Chris K et al. (2018) Audiologic Natural History of Small Volume Cochleovestibular Schwannomas in Neurofibromatosis Type 2. Otol Neurotol 39:357-364
Dewan, Ramita; Pemov, Alexander; Dutra, Amalia S et al. (2017) First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation. BMC Cancer 17:127
Montgomery, Blake K; Alimchandani, Meghna; Mehta, Gautam U et al. (2016) Tumors displaying hybrid schwannoma and neurofibroma features in patients with neurofibromatosis type 2. Clin Neuropathol 35:78-83
Mehta, Gautam U; Feldman, Michael J; Wang, Herui et al. (2016) Unilateral vestibular schwannoma in a patient with schwannomatosis in the absence of LZTR1 mutation. J Neurosurg 125:1469-1471
Perera, Andrea P; Mehta, Gautam U; Pratt, Drew et al. (2016) Diagnosis of a growing radiation-induced skull lesion in a patient: an unusual scar. J Neurosurg 125:561-4
Dewan, Ramita; Pemov, Alex; Kim, H Jeffrey et al. (2015) Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas. Neuro Oncol 17:566-73
Holliday, Michael A; Kim, Hung Jeffrey; Zalewski, Christopher K et al. (2014) Audiovestibular Characteristics of Small Cochleovestibular Schwannomas in Neurofibromatosis Type 2. Otolaryngol Head Neck Surg 151:117-24
Asthagiri, Ashok R; Vasquez, Raul A; Butman, John A et al. (2012) Mechanisms of hearing loss in neurofibromatosis type 2. PLoS One 7:e46132

Showing the most recent 10 out of 12 publications